Comparison

“GLOW” vs “Wolverine”:
identity, evidence and legal status

Two names for pre-mixed vials, differing by one listed peptide. The same questions asked of both, component by component, and no verdict: we found no study of either mix as sold.

Short answerCompound research · 6 min read · Updated 21 Nov 2026

GLOW and “Wolverine” are seller names for pre-mixed vials. GLOW lists three peptides, GHK-Cu, BPC-157 and TB-500; “Wolverine” lists the last two. The difference is GHK-Cu, which has its own cell, animal and small human skin studies. We found no study of either mix as sold, and no controlled study in people of BPC-157 with TB-500 (21 November 2026).

Key takeaways

  • GLOW is a seller name for one vial that lists GHK-Cu, BPC-157 and TB-500; “Wolverine” is a seller name for one that lists BPC-157 and TB-500. The difference is GHK-Cu.
  • We found no published study or registered trial of either mix as sold, and none comparing them (PubMed and ClinicalTrials.gov, 21 Nov 2026).
  • GHK-Cu’s own record, in the studies cited here, is cell and animal work plus one small randomised skin study in people; none of it transfers to a mixed vial.
  • Regulators and WADA set status one compound at a time, and none of the status documents we read names either mix.
  • A lab report for a vial that lists three peptides has three identities to confirm; for two peptides, two.

01GLOW and “Wolverine” side by side

The same questions, asked of two names for pre-mixed vials. Dated 21 November 2026.

QuestionGLOW“Wolverine”
What the name refers toA seller name for one vial that mixes three peptidesA seller name for one vial that mixes two peptides
Listed componentsGHK-Cu, BPC-157, TB-500BPC-157, TB-500
The component that differsGHK-Cu is listedGHK-Cu is not listed
Studied as a mixNo study found, in any speciesNo study of a vial sold under the name. Three papers we found gave BPC-157 with TB-500 or thymosin β4: a 2026 rat study and two uncontrolled human reports
Compared with the otherNo study foundNo study found
Evidence tier of the studies cited here, component by componentGHK-Cu: one small randomised skin study in people (T1), plus animal (T3) and cell (T4) studies. BPC-157: small human studies (T2) and animal studies (T3). TB-500: animal and cell studies (T3, T4)BPC-157 and TB-500 as on the left
United StatesDrugs@FDA lists no medicine containing any of the three. FDA’s list of substances nominated for compounding (updated 14 May 2026) places GHK-Cu, for certain routes of administration only, in Category 1, under evaluation. HHS’s October 2026 draft policy, which “is not binding”, names BPC-157 and TB-500, not GHK-Cu, and covers single-ingredient products onlyBPC-157 and TB-500 as on the left
AustraliaThe TGA says that “many products promoted online are unapproved therapeutic goods and may be unlawful to import, supply or advertise. Using unapproved peptide products can pose serious health risks.” BPC-157 and TB-500 are in Schedule 4 and Appendix D of the Poisons Standard October 2026. GHK-Cu has no entry by name, and the standard has group entries for copper compounds; we draw no scheduling conclusion of our ownBPC-157 and TB-500 as on the left, with the same TGA sentence
United KingdomThe emc database returned no results for GHK, BPC-157 or TB-500 (21 Nov 2026); it is not the full UK registerThe same for BPC-157 and TB-500
Sport (WADA 2026 and 2027 Lists)BPC-157 (class S0) and TB-500 (class S2.3) are named, prohibited at all times. GHK-Cu is not named, and WADA says a peptide not specifically named “may still be prohibited”BPC-157 and TB-500 as on the left
Identities a lab report has to confirmThreeTwo

If you searched “glow vs wolverine peptide”, the two names differ by one listed component, and what is known about that component is not known about either mix. To see what each name covers: what is the “GLOW peptide”? and what is the “Wolverine peptide”?

02What does GHK-Cu add to the listed components?

One extra molecule on one side. The drawings show which molecules are listed, not how much of each.

Identity

GHK-Cu: the extra molecule

Glycyl-L-histidyl-L-lysine, a peptide of three amino acids, holding a copper(II) ion. The earliest papers we found on GHK in PubMed date from 1973.

Mix

GLOW: three listed names

GHK-Cu with BPC-157 and TB-500 in one vial. No regulator or peer-reviewed source defines the mix or says how much of each it holds.

Mix

Wolverine: two listed names

BPC-157 and TB-500 in one vial. Again no source defines the mix or the amounts, and GHK-Cu is not listed.

What is known about GHK-Cu is not known about either mix. Evidence attaches to what was studied, never to a name for a mix: peptide blends: one vial, no shared evidence.

03What has GHK-Cu been studied in, and has any study covered the pair or the trio?

GHK-Cu’s own record, design and measures only. None of these studies gave GHK-Cu with another peptide.

StudyModel and nWhat was measuredTier
Miller et al., 2006People: a randomised comparison of skin-care regimens with or without GHK-Cu after laser resurfacing around the mouth; 13 completedRedness, by software and blinded evaluators; wrinkles and skin quality at 12 weeks; a patient questionnaireT1, small
Maquart et al., 1993Rats with implanted wound chambers; n not given in the abstractDry weight, protein, collagen and DNA content of the chamber tissueT3
Maquart et al., 1988Fibroblasts in cultureCollagen production by the cellsT4

An animal or cell result is not evidence of an effect in people, and material sold online is not the product these studies tested. GHK-Cu’s guide grades its human evidence “Early human”: the GHK-Cu guide.

What the pair has, and the trio lacks. Three papers we found gave BPC-157 with TB-500 or thymosin β4: a 2026 study in rats after Achilles tendon repair, a 2026 report of three patients who also received other agents, and a 2021 chart review in which four patients received BPC-157 with thymosin β4; neither human report had a control group. We found no study that added GHK-Cu to them. On 21 November 2026 PubMed returned 7 papers naming GHK-Cu, BPC-157 and TB-500 or thymosin β4 together; by publication type and title each is a review, commentary or letter. ClinicalTrials.gov lists no trial that gives two or more of the three together.

04Where do the three components stand with regulators and in sport?

Component by component. None of the status documents we read names either mix.

  1. Sep 2023FDA Category 2

    BPC-157 and TB-500 enter FDA’s list of compounding substances that may present significant safety risks.

  2. 22 Apr 2026Out of Category 2

    HHS records that neither the placement nor the removal changed the status of the two under section 503A.

  3. 14 May 2026GHK-Cu under evaluation

    FDA’s updated list places GHK-Cu, for certain routes of administration only, in Category 1. FDA says it intends to consult its compounding advisory committee before the end of February 2027.

  4. 1 Oct 2026Poisons Standard October 2026 in force

    Australia’s current standard lists BPC-157 and TB-500 in Schedule 4 and Appendix D. We found no entry by name for GHK-Cu.

  5. 30 Oct 2026HHS draft policy published

    It names six peptides, including BPC-157 and TB-500, not GHK-Cu, and applies only when a product “contains only a single Active Pharmaceutical Ingredient (API) listed in Appendix A”. The notice calls it a draft that “is not binding”.

  6. 1 Jan 2027WADA 2027 List takes effect

    BPC-157 (class S0) and TB-500 (class S2.3) remain named. GHK-Cu is not named, and WADA says a peptide not specifically named “may still be prohibited”.

Each component, country by country: BPC-157, TB-500 and GHK-Cu. Sport: peptides and anti-doping.

05What we don’t know, and what would have to be studied

There is no measurement on which to rank one name against the other. These are the studies that would be needed.

1
Stability of each mix

Whether the peptides stay intact together in one vial, and for how long, for two peptides and for three. We found none in PubMed (21 Nov 2026).

2
Each mix against its components

The same model and measures, with a group for each peptide alone, a group for BPC-157 with TB-500, and a group for all three.

3
GHK-Cu as the only difference

A direct comparison of the pair with the trio, in which GHK-Cu is the single change. We found none, published or registered.

4
What a given vial holds

Only that lot’s lab report can show it: two identities and two amounts for a two-peptide vial, three of each for a three-peptide vial.

How to read those lines on a report: how to read a COA.

This is a plain-English summary of public documents and studies, checked on 21 Nov 2026. It is not legal or medical advice.

RefSources

  1. Pickart L, Margolina A. [Review of GHK-Cu research.] Int J Mol Sci, 2018;19(7):1987. PMID 29986520; identity section read 21 Nov 2026. pmc.ncbi.nlm.nih.gov/articles/PMC6073405/
  2. Pickart L, Thaler MM. [Report of a tripeptide in human serum, tested on liver cells in culture.] Nat New Biol, 1973;243(124):85–87. PMID 4349963; PubMed record (no abstract) read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/4349963/
  3. Miller TR, Wagner JD, Baack BR, Eisbach KJ. [Randomised skin-care comparison after laser resurfacing.] Arch Facial Plast Surg, 2006;8(4):252–259. PMID 16847171; abstract read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/16847171/
  4. Maquart FX, Bellon G, Chaqour B, et al. [Connective-tissue measurements in a rat wound-chamber model.] J Clin Invest, 1993;92(5):2368–2376. PMID 8227353; abstract read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/8227353/
  5. Maquart FX, Pickart L, Laurent M, et al. [Collagen measurements in fibroblast cultures.] FEBS Lett, 1988;238(2):343–346. PMID 3169264; abstract read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/3169264/
  6. PubMed record. Biçer O, et al. [Rat Achilles tendon repair study with groups given BPC-157, TB-500 and both.] Jt Dis Relat Surg, 2026. PMID 42542926; record read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/42542926/
  7. Froum S, Estrin N, Pico G, et al. [Narrative review with three uncontrolled clinical cases given several agents, including BPC-157 and TB-500.] Front Oral Health, 2026;7:1907109. PMID 42876687; full text PMC13661421 read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/42876687/
  8. Lee E, Padgett B. [Retrospective chart review of BPC-157, alone or with thymosin β4, in 16 patients.] Altern Ther Health Med, 2021;27(4):8–13. PMID 34324435; record read 21 Nov 2026. pubmed.ncbi.nlm.nih.gov/34324435/
  9. PubMed searches, 21 Nov 2026 (title and abstract): (GHK OR GHK-Cu OR copper tripeptide OR prezatide) AND (BPC OR BPC-157 OR pentadecapeptide OR bepecin) AND (TB-500 OR TB500 OR thymosin beta names), 7 results; BPC-157 names AND TB-500 or thymosin beta names, 17; GLOW or Wolverine with peptide names, 0. pubmed.ncbi.nlm.nih.gov/?term=%28GHK%5Btiab%5D+OR+GHK-Cu%5Bt…
  10. ClinicalTrials.gov. Intervention searches for GHK-Cu (4 records), BPC-157 (4), TB-500 (1) and the words GLOW peptide and Wolverine (none about peptides): no record gives two or more of the three together. Registry searches through API v2, 21 Nov 2026. clinicaltrials.gov/search?intr=GHK-Cu
  11. U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A (categories 1 to 3), including the GHK-Cu update. List updated 14 May 2026; downloaded and read 21 Nov 2026. www.fda.gov/media/94155/download
  12. U.S. Food and Drug Administration. Drugs@FDA data through the openFDA API (data last updated 20 Nov 2026): no product matches GHK, prezatide, BPC-157, thymosin or KPV as an active ingredient (control search, somatropin: 12 records). Database queries, 21 Nov 2026. api.fda.gov/drug/drugsfda.json?limit=1
  13. U.S. Department of Health and Human Services. Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances, with Appendices A and B. Policy document, Oct 2026; read 21 Nov 2026 on the Internet Archive capture of 15 Nov 2026, the newest readable one (hhs.gov returned 403 to our tools). web.archive.org/web/20261115103435/https://www.hhs.gov/sites…
  14. Federal Register 91 FR 68526, FR Doc. 2026-22192. Notice of availability: Enforcement discretion policy regarding 503A compounding using certain peptide bulk drug substances. Notice, 30 Oct 2026; text read on govinfo 21 Nov 2026. www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.ht…
  15. Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026 (F2026L01327): Schedule 4 and Appendix D, clause 5. Federal Register of Legislation, registered 30 Sep 2026, commenced 1 Oct 2026; as-made text searched 21 Nov 2026. www.legislation.gov.au/F2026L01327/latest/text
  16. Therapeutic Goods Administration. Peptide products. Topic page, last updated 23 Sep 2026; read 21 Nov 2026 on the Internet Archive capture of 5 Nov 2026, the newest (tga.gov.au did not respond to our tools). web.archive.org/web/20261105200754/https://www.tga.gov.au/re…
  17. World Anti-Doping Agency. Prohibited List 2027 (in force 1 Jan 2027), classes S0 and S2.3, read beside the 2026 List, and the 2027 summary of major modifications and explanatory notes (undated in its text). International Standard; PDFs downloaded 21 Nov 2026 (SHA-1 8e84d248… and 08b06d5a…) and searched. www.wada-ama.org/sites/default/files/2026-11/2027list_en_fin…
  18. Electronic medicines compendium (emc). Searches for GHK, copper tripeptide, KPV, BPC-157 and TB-500: “No search results” for each (control search, somatropin: 21 results). Database searches, 21 Nov 2026. www.medicines.org.uk/emc/search?q=GHK

Plain-English summary of public sources, not legal or medical advice. Last checked 21 Nov 2026.

Questions

What is the difference between GLOW and “Wolverine”?

One listed peptide. GLOW is a seller name for a vial that mixes GHK-Cu, BPC-157 and TB-500; “Wolverine” is a seller name for a vial that mixes BPC-157 and TB-500.

Has any study compared GLOW with “Wolverine”?

Not that we found (PubMed and ClinicalTrials.gov, 21 Nov 2026). We found no study of either mix as sold, so there is nothing to compare.

What has GHK-Cu itself been studied in?

Cells, animals and small human skin studies, among them a randomised one (Miller 2006, 13 completers). We found no study that gave it with BPC-157 or TB-500 (21 Nov 2026), so its record does not transfer to either mix.

Are the components named on WADA’s Prohibited List?

BPC-157 (class S0) and TB-500 (class S2.3) are named as prohibited at all times. GHK-Cu is not named, and WADA says a peptide not specifically named “may still be prohibited”.

How many identities does a lab report have to confirm?

Three for a vial that lists GLOW’s components and two for one that lists “Wolverine”’s: each peptide identified and measured on its own.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page